Phase II Trial of Elderly Patients With Newly Diagnosed Multiple Myeloma

Video

María-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.

Clinical Pearls

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.

  • The GEM2010MAS65 trial compared sequential and alternating administration of bortezomib, melphalan, and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma
  • The alternating scheme showed superior efficacy in terms of complete remission
  • Longer follow-up is needed
Related Videos
Related Content